Executive transition There is a leadership change upcoming with a new CEO effective August 1, 2026. This offers an opportunity to engage the new executive team with Tristel’s infection prevention solutions, capitalizing on messaging around continuity, innovation, and growth plans.

High level disinfection focus Tristel’s core products for high-level disinfection of medical devices (Tristel) and sporicidal environmental surfaces (Cache) position the company to pursue hospitals expanding or reforming infection prevention protocols, including ultrasound probe disinfection where APIC26 discussions highlight real-world adoption.

Growing revenue band With reported revenue in the $100M–$250M range and a leaner employee base relative to peers, there is potential to scale partnerships, channel distribution, and contract-driven sales with hospitals and regional health systems seeking cost-effective infection prevention solutions.

Strategic partnerships Active engagement in industry events (APIC, AORN) and collaborations (co-sponsoring with Parker Laboratories on chlorine dioxide foam) indicate a receptiveness to co-marketing and bundled offerings that can be leveraged to expand adoption across clinical departments and facilities.

Sustainability & safety emphasis ClO2-based disinfection aligns with stringent infection control and safety standards. This can be marketed to procurement and infection prevention teams as a sustainable, effective solution with potential for long-term contracts, documentation, and training services.